Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
News|Articles|November 20, 2014
Vetter Opens New Office in Singapore to Support Growing Asian Market
Author(s)Pharmaceutical Technology Editors
CDMO Vetter has opened a new representative office in Singapore in response to growing market demand in Asia.
Advertisement
CDMO Vetter, a specialist in aseptic fill and finish of injection systems for the bio/pharmaceutical industry, has opened a new representative office in Singapore in response to growing market demand in Asia. The announcement was made at a ceremony attended by members of local government agencies, a number of executives of pharmaceutical/biotech companies in the Asian region, and Vetter executives.
The new office, headed by Chervee Ho, director, Key Account Management, Asia Pacific, will enable the company to better serve the Asian market, which was previously handled by Vetter’s German-based departments.
Source:
Advertisement
Related to this article
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
3
Pfizer's 8-Month Path from Candidate to IND: AAPS PharmSci 360 2026
4
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
5